Current status and progress in the treatment of congenital liver cyst
Keywords:Congenital liver cyst, Treatment, Progress, Review
Liver cyst is a relatively common benign liver disease. According to the cause of the disease, it can be divided into two types: non-parasitic liver cyst and parasitic liver cyst. Congenital liver cyst is the most common non-parasitic liver cyst in clinical practice, also known as true cyst, which mainly include simple liver cyst and polycystic liver diseases (PLD). In recent years, with the popularization of ultrasound and other examinations, the detection rate of liver cyst has increased year by year, but there is no unified consensus on the treatment of liver cysts. This article reviews the conservative treatment, puncture drainage, aspiration sclerotherapy, surgical treatment and other treatment options for congenital liver cysts, as well as the technological progress in recent years.
Laarschot LFM, Drenth JPH. Genetics and mechanisms of hepatic cystogenesis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4):1491-7.
Marrero JA, Ahn J, Rajender Reddy K, Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014;109(9):1328-47.
Vardakostas D, Damaskos C, Garmpis N, Antoniou EA, Kontzoglou K, Kouraklis G, et al. Minimally invasive management of hepatic cysts: indications and complications. Eur Rev Med Pharmacol Sci. 2018;22(5):1387-96.
Yang F, Qian Z, Sun F, Chen K, Fan L, Duan J, et al. Laparoscopic Enucleation of Hepatic Cysts Reduces the Recurrence of Nonparasitic Hepatic Cysts. J Laparoendosc Adv Surg Tech A. 2021;31(3):314-9.
Xu S, Rao M, Pu Y, Zhou J, Zhang Y. The efficacy of laparoscopic lauromacrogol sclerotherapy in the treatment of simple hepatic cysts located in posterior segments: a refined surgical approach. Ann Palliat Med. 2020;9(5):3462-71.
Lee DS, Lee SK, Seo DW. Long-term safety and efficacy of ethanol retention therapy via percutaneous approach and/or EUS guidance for symptomatic large hepatic cysts. Endosc Ultrasound. 2020;9(1):31-6.
Wijnands TF, Schoenemeier B, Potthoff A, Gevers TJ, Groenewoud H, Gebel MJ, Rifai K, Manns MP, et al. Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts. United European Gastroenterol J. 2018 Jul;6(6):919-25.
Danza FM, Falcione M, Bordonaro V, Infante A, Paladini A, Bonomo L. Minocycline hydrochloride as a soft sclerotizing agent for symptomatic simple renal and hepatic cysts. Eur Rev Med Pharmacol Sci. 2017;21(2):408-15.
Neijenhuis MK, Wijnands TFM, Kievit W, Ronot M, Gevers TJG, Drenth JPH. Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts. Eur Radiol. 2019;29(6):3062-8.
Wijnands TF, Ronot M, Gevers TJ, Benzimra J, Kool LJ, Vilgrain V, et al. Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data. Eur Radiol. 2017;27(2):741-8.
Wijnands TF, Görtjes AP, Gevers TJ, Jenniskens SF, Kool LJ, Potthoff A, et al. Efficacy and Safety of Aspiration Sclerotherapy of Simple Hepatic Cysts: A Systematic Review. AJR Am J Roentgenol. 2017;208(1):201-7.
Jang SY, Park SY, Tak WY, Kweon YO, Ryeom H. Long-term follow-up of large symptomatic hepatic cysts treated by percutaneous ethanol sclerotherapy. Acta Radiol. 2016;57(10):1205-9.
Clancy C, Gibbons C, Ridgway PF. Surgical management of a giant hepatic cyst with suspicious radiological features. Ann R Coll Surg Engl. 2019;101(3):76-8.
Gomez A, Wisneski AD, Luu HY, Hirose K, Roberts JP, Hirose R, et al. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center. J Gastrointest Surg. 2021;25(1):77-84.
Agnolo HM, Kievit W, Munster KN, Laan JJ, Nevens F, Drenth JP. Center is an important indicator for choice of invasive therapy in polycystic liver disease. Transpl Int. 2017;30(1):76-82.
Aerts RMM, Laarschot LFM, Banales JM, Drenth JPH. Clinical management of polycystic liver disease. J Hepatol. 2018;68(4):827-37.
Agnolo HM, Drenth JP. Risk factors for progressive polycystic liver disease: where do we stand? Nephrol Dial Transplant. 2016;31(6):857-9.
Zhang ZY, Wang ZM, Huang Y. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management. World J Hepatol. 2020;12(3):72-83.
Bernts LHP, Echternach SG, Kievit W, Rosman C, Drenth JPH. Clinical response after laparoscopic fenestration of symptomatic hepatic cysts: a systematic review and meta-analysis. Surg Endosc. 2019;33(3):691-704.
Chebib FT, Harmon A, Irazabal MV, Jung YS, Edwards ME, Hogan MC, et al. Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease. J Am Coll Surg. 2016;223(1):118-26.
Bernts LHP, Neijenhuis MK, Edwards ME, Sloan JA, Fischer J, Smoot RL, et al. Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease. Surgery. 2020;168(1):25-32.
Hoshino J, Ubara Y, Suwabe T, Sumida K, Hayami N, Mise K, Hiramatsu R, et al. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63(6):937-44.
Yan JY, Zhang JL, Yuan K, Fu JX, Wang Y, Yuan B, et al. Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate -Lipiodol mixture for symptomatic polycystic liver disease: preliminary experience. Clin Radiol. 2019;74(12):975.
Zhang JL, Yuan K, Wang MQ, Yan JY, Xin HN, Wang Y, et al. Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up. Chin Med J. 2017;130(16):1938-44.
Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, et al. Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int. 2011;24(12):1239-45.
Ding F, Tang H, Zhao H, Feng X, Yang Y, Chen GH, et al. Long-term results of liver transplantation for polycystic liver disease: Single-center experience in China. Exp Ther Med. 2019;17(5):4183-9.
Doshi SD, Bittermann T, Schiano TD, Goldberg DS. Waitlisted Candidates with Polycystic Liver Disease Are More Likely to be Transplanted Than Those with Chronic Liver Failure. Transplantation. 2017;101(8):1838-44.
Coquillard C, Berger J, Daily M, Shah M, Mei X, Marti F, et al. Combined liver-kidney transplantation for polycystic liver and kidney disease: analysis from the United Network for Organ Sharing dataset. Liver Int. 2016;36(7):1018-25.
Larusso NF, Masyuk TV, Hogan MC. Polycystic Liver Disease: The Benefits of Targeting cAMP. Clin Gastroenterol Hepatol. 2016;14(7):1031-4.
Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, et al. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc. 2015;90(8):1030-7.
Aerts RMM, Kolkman M, Kievit W, Gevers TJG, Nevens F, Drenth JPH. Drug holiday in patients with polycystic liver disease treated with somatostatin analogues. Therap Adv Gastroenterol. 2018;11:84.
Aerts RMM, Kievit W, Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, et al. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. Gastroenterology. 2019 Aug;157(2):481-91.
Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, Oftsie T, et al. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1267-78.
Masyuk TV, Masyuk AI, LaRusso NF. Therapeutic Targets in Polycystic Liver Disease. Curr Drug Targets. 2017;18(8):950-7.
Masyuk AI, Masyuk TV, Lorenzo PMJ, Ding JF, Loarca L, Huang BQ, et al. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target. Hepatology. 2018;67(3):1088-108.